Showing results (181-190 of 254) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II studyAnas Younes, Anna Sureda, Dina Ben-Yehuda, et al.Cancers|July 5, 2019
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence TreatmentNicole Wong Doo, Victoria M White, Kara Martin, et al.Australian Health Review : a Publication of the Australian Hospital Association|December 1, 2011
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatmentSenthil Lingaratnam, Leon J Worth, Monica A Slavin, et al.Eye (London, England)|November 27, 2010
Best's macular dystrophy in Australia: phenotypic profile and identification of novel BEST1 mutationsA C Cohn, C Turnbull, J B Ruddle, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
In vivo tracking of dendritic cells in patients with multiple myelomaH Miles Prince, Dominic M Wall, David Ritchie, et al.Pathology|January 7, 2020
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupM Gohar Maqbool, Constantine S Tam, Ian M Morison, et al.Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myelomaH Miles Prince, Linda Mileshkin, Andrew Roberts, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.Pageof 26